World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
89
Citations
28262
World Ranking
12716
National Ranking
6501

Research.com Recognitions

  • 2015 - Fellow of the American Statistical Association (ASA)

Overview

Peter F. Thall is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research spans multiple disciplines, primarily focusing on medicine and mathematics, with a significant emphasis on statistics and probability. Their work includes contributions to hematology, oncology, molecular biology, and economics and econometrics.

The scientist's main research topics include:

  • Statistical Methods in Clinical Trials
  • Health Systems, Economic Evaluations, Quality of Life
  • Acute Myeloid Leukemia Research
  • Advanced Causal Inference Techniques
  • Hematopoietic Stem Cell Transplantation
  • Cancer Genomics and Diagnostics
  • Optimal Experimental Design Methods

Peter F. Thall has published extensively in prominent journals. Frequent publication venues include:

  • Blood
  • Transplantation and Cellular Therapy
  • Biometrics
  • Journal of Clinical Oncology
  • Cancers

Their recent notable papers include:

  • Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors, 2020, New England Journal of Medicine
  • Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial, 2024, Nature Medicine
  • A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients, 2020, Blood Advances
  • Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer, 2020, Science Translational Medicine
  • Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation, 2021, Journal of Clinical Oncology

Frequent co-authors of Peter F. Thall include:

  • Elizabeth J. Shpall
  • Richard E. Champlin
  • Uday Popat
  • Chitra Hosing
  • Yago Nieto

In addition to journal publications, Peter F. Thall has contributed to book literature. One such book is Statistical Remedies for Medical Researchers, published by Springer International Publishing in 2020.

The scientist has been recognized as a Fellow of the American Statistical Association (ASA), awarded in 2015.

Best Publications

  • Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

    Enli Liu;David Marin;Pinaki Banerjee;Homer A. Macapinlac

  • Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

    Sergio Giralt;Peter F. Thall;Issa Khouri;Xuemei Wang

  • Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas

    Robert G. Maki;J. Kyle Wathen;Shreyaskumar R. Patel;Dennis A. Priebat

  • Some covariance models for longitudinal count data with overdispersion.

    Peter F. Thall;Stephen C. Vail

  • Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS

    Marcos de Lima;Daniel Couriel;Peter F. Thall;Xuemei Wang

  • Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.

    Marcos J.G. de Lima;Sergio Giralt;Peter F. Thall;Leandro De Padua Silva

  • Dose‐Finding Based on Efficacy–Toxicity Trade‐Offs

    Peter F. Thall;John D. Cook

  • Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

    Ana M. Aparicio;Andrea L. Harzstark;Paul G. Corn;Sijin Wen;Sijin Wen

  • Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.

    E Estey;P Thall;M Andreeff;M Beran

  • Neoadjuvant Paclitaxel, Ifosfamide, and Cisplatin Chemotherapy for Metastatic Penile Cancer: A Phase II Study

    Lance C. Pagliaro;Dallas L. Williams;Danai Daliani;Michael B. Williams

  • Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes.

    Peter F. Thall;Richard M. Simon;Elihu H. Estey

  • Multi-Institutional Study of Post-Transplantation Cyclophosphamide As Single-Agent Graft-Versus-Host Disease Prophylaxis After Allogeneic Bone Marrow Transplantation Using Myeloablative Busulfan and Fludarabine Conditioning

    Christopher G. Kanakry;Paul V. O'Donnell;Terry Furlong;Marcos J. De Lima

  • Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.

    Elihu H. Estey;Peter F. Thall;Sherry Pierce;Jorge Cortes

  • A STRATEGY FOR DOSE-FINDING AND SAFETY MONITORING BASED ON EFFICACY AND ADVERSE OUTCOMES IN PHASE I/II CLINICAL TRIALS

    Peter F. Thall;Kathy E. Russell

  • High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation.

    Stefan O. Ciurea;Marcos J.G. de Lima;Pedro Cano;Martin Korbling

  • Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy

    Elihu Estey;Peter Thall;Miloslav Beran;Hagop Kantarjian

  • Propensity Score-based Comparison of Long-term Outcomes With 3-Dimensional Conformal Radiotherapy vs Intensity-Modulated Radiotherapy for Esophageal Cancer

    Steven Hsesheng Lin;Lu Wang;Bevan Myles;Peter F Thall

  • Prognostic significance of preoperative MRI scans in glioblastoma multiforme.

    Maarouf A. Hammoud;Raymond Sawaya;Weiming Shi;Peter F. Thall

  • Results of a Phase II Study With Doxorubicin, Etoposide, and Cisplatin in Patients With Fully Characterized Small-Cell Carcinoma of the Prostate

    Christos N. Papandreou;Danai D. Daliani;Peter F. Thall;Shi Ming Tu

  • Practical Bayesian adaptive randomisation in clinical trials

    Peter F. Thall;J. Kyle Wathen

Frequent Co-Authors

Richard E. Champlin
Richard E. Champlin The University of Texas MD Anderson Cancer Center
Borje S. Andersson
Borje S. Andersson The University of Texas MD Anderson Cancer Center
Partow Kebriaei
Partow Kebriaei The University of Texas MD Anderson Cancer Center
Elizabeth J. Shpall
Elizabeth J. Shpall The University of Texas MD Anderson Cancer Center
Sergio Giralt
Sergio Giralt Memorial Sloan Kettering Cancer Center
Elihu H. Estey
Elihu H. Estey University of Washington
Xuemei Wang
Xuemei Wang The University of Texas MD Anderson Cancer Center
Issa F. Khouri
Issa F. Khouri The University of Texas MD Anderson Cancer Center
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Robert Z. Orlowski
Robert Z. Orlowski The University of Texas MD Anderson Cancer Center

External Links

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA isn’t the only way to launch a healthcare career. Many students consider online programs and alternative pathways that can offer greater flexibility and affordability. For example, pursuing an online pharmacy degree can lead to excellent job prospects in pharmaceutical care, often with competitive salaries.

Another in-demand field is health data management. Accredited online schools for health information management train students to organize, analyze, and secure sensitive patient data, preparing them for diverse roles in medical administration and technology.

For those interested in administrative careers, medical billing and coding is a rapidly growing field. Prospective students often weigh the medical coding certification cost to make informed decisions about this short-term, career-ready option.

Finally, nursing careers remain a mainstay in healthcare. If becoming a nurse practitioner is your goal, exploring the cheapest online fnp program may provide a cost-effective way to gain advanced clinical skills and help fill the national nurse shortage.

Best Scientists Citing Peter F. Thall

Trending Scientists